MARKET SHARE OF GENERIC MEDICINES TO REACH 60% IN PORTUGAL
Brussels, 15 July 2014 - The European Generic medicines Association (EGA) – and APOGEN – the Portuguese Generic medicines Association, congratulate the Portuguese Pharmacies Association and the Ministry of Health for their agreement to set an objective of a 60% market share for generic medicines.
This agreement will enable pharmacies to provide public health services to the population and encourage them to meet the generic medicines objective.
EGA CALLS ON THE COMMISSION TO CONDUCT FULLY-FLEDGED EFFECT ANALYSES ON PATENT SETTLEMENTS
Brussels, 9 July 2014 - The European Commission (EC) today communicated its decision on the Perindopril case, through which certain patent settlement agreements were deemed to be in breach of competition law. The EGA is not in a position to comment on the facts of the case, which remain confidential, or on the merits of the EC decision.
EUROPEAN BIOSIMILARS GROUP RE-APPOINTS STRONG LEADERSHIP TEAM
Brussels, 9 July 2014 - Today the European Biosimilars Group (EBG), EGA sector group, has re-elected
- Joerg Windisch, Chief Science Officer, Sandoz as EBG Chair
- Ildiko Aradi, Head Clinical Development of Biologics, Gedeon Richter,
- Karl Heinz Emmert, Head Biosimilar Project Champions, Teva as Vice-Chairs and
21 January 2015
22 - 23 January 2015
KPMG Report - Advice on the implementation of EU-Directive 2011/62/EU
Advice on the implementation of EU-Directive 2011/62/EU
KPMG Report Download PDF
EGA Biosimilars Handbook
EGA Biosimilars Handbook English version EGA_BIOSIMILARS_handbook_en.pdf
EGA Biosimilars Handbook German version EGA_Biosimilars_ProGen-Biosimilars-A5-RZ-web_ende.pdf
EGA Biosimilars Handbook Italian version EGA_BIOSIMILARS_IT.pdf
EGA Biosimilars Handbook Spanish version EGA_BIOSIMILARS_INT_Spain.pdf
EGA Q&A on the revised EMA Bioequivalence Guideline
EGA Q&A on the revised EMA Bioequivalence Guideline, the EGA Contribution to the Promotion of Harmonised EU interpretation of the revised Bioequivalence Requirement dowload PDF
EGA Vision 2015, the Way forward for more Efficient Regulatory Environment for Generic and Biosimilar Medicines